IRMD Stock Recent News
IRMD LATEST HEADLINES
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005.
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.